Cargando…
Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390119/ https://www.ncbi.nlm.nih.gov/pubmed/30815369 http://dx.doi.org/10.5306/wjco.v10.i2.28 |
_version_ | 1783398077599580160 |
---|---|
author | Braga, Antonio Mora, Paulo de Melo, Andréia Cristina Nogueira-Rodrigues, Angélica Amim-Junior, Joffre Rezende-Filho, Jorge Seckl, Michael J |
author_facet | Braga, Antonio Mora, Paulo de Melo, Andréia Cristina Nogueira-Rodrigues, Angélica Amim-Junior, Joffre Rezende-Filho, Jorge Seckl, Michael J |
author_sort | Braga, Antonio |
collection | PubMed |
description | Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score ≤ 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women. |
format | Online Article Text |
id | pubmed-6390119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-63901192019-02-27 Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide Braga, Antonio Mora, Paulo de Melo, Andréia Cristina Nogueira-Rodrigues, Angélica Amim-Junior, Joffre Rezende-Filho, Jorge Seckl, Michael J World J Clin Oncol Editorial Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score ≤ 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women. Baishideng Publishing Group Inc 2019-02-24 2019-02-24 /pmc/articles/PMC6390119/ /pubmed/30815369 http://dx.doi.org/10.5306/wjco.v10.i2.28 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial Braga, Antonio Mora, Paulo de Melo, Andréia Cristina Nogueira-Rodrigues, Angélica Amim-Junior, Joffre Rezende-Filho, Jorge Seckl, Michael J Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
title | Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
title_full | Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
title_fullStr | Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
title_full_unstemmed | Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
title_short | Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
title_sort | challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390119/ https://www.ncbi.nlm.nih.gov/pubmed/30815369 http://dx.doi.org/10.5306/wjco.v10.i2.28 |
work_keys_str_mv | AT bragaantonio challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide AT morapaulo challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide AT demeloandreiacristina challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide AT nogueirarodriguesangelica challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide AT amimjuniorjoffre challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide AT rezendefilhojorge challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide AT secklmichaelj challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide |